Keros Therapeutics (KROS) EBT Margin (2019 - 2025)
Keros Therapeutics' EBT Margin history spans 6 years, with the latest figure at 4328.42% for Q4 2025.
- For Q4 2025, EBT Margin fell 1332960.0% year-over-year to 4328.42%; the TTM value through Dec 2025 reached 37.62%, down 15583988.0%, while the annual FY2025 figure was 37.65%, N/A changed from the prior year.
- EBT Margin reached 4328.42% in Q4 2025 per KROS's latest filing, down from 61.03% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1583500.0% in Q1 2021 to a low of 541000.0% in Q3 2023.
- Average EBT Margin over 5 years is 82090.59%, with a median of 157.78% recorded in 2022.
- Peak YoY movement for EBT Margin: plummeted -158363437bps in 2022, then skyrocketed 52735155bps in 2024.
- A 5-year view of EBT Margin shows it stood at 27.6% in 2021, then tumbled by -387bps to 134.37% in 2022, then crashed by -24077bps to 32486.01% in 2023, then surged by 128bps to 9001.18% in 2024, then tumbled by -148bps to 4328.42% in 2025.
- Per Business Quant, the three most recent readings for KROS's EBT Margin are 4328.42% (Q4 2025), 61.03% (Q3 2025), and 181.19% (Q2 2025).